Growth Metrics

Myriad Genetics (MYGN) Shares Outstanding (Weighted Average) (2016 - 2026)

Myriad Genetics has reported Shares Outstanding (Weighted Average) over the past 17 years, most recently at $92.6 million for Q4 2025.

  • Quarterly Shares Outstanding (Weighted Average) rose 2.21% to $92.6 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $92.6 million through Dec 2025, up 2.21% year-over-year, with the annual reading at $92.6 million for FY2025, 2.21% up from the prior year.
  • Shares Outstanding (Weighted Average) was $92.6 million for Q4 2025 at Myriad Genetics, roughly flat from $92.3 million in the prior quarter.
  • Over five years, Shares Outstanding (Weighted Average) peaked at $92.6 million in Q4 2025 and troughed at $76.0 million in Q1 2021.
  • The 5-year median for Shares Outstanding (Weighted Average) is $81.8 million (2023), against an average of $84.5 million.
  • Year-over-year, Shares Outstanding (Weighted Average) increased 1.5% in 2023 and then increased 10.99% in 2024.
  • A 5-year view of Shares Outstanding (Weighted Average) shows it stood at $78.0 million in 2021, then grew by 3.33% to $80.6 million in 2022, then rose by 2.73% to $82.8 million in 2023, then grew by 9.42% to $90.6 million in 2024, then grew by 2.21% to $92.6 million in 2025.
  • Per Business Quant, the three most recent readings for MYGN's Shares Outstanding (Weighted Average) are $92.6 million (Q4 2025), $92.3 million (Q3 2025), and $92.5 million (Q2 2025).